Literature DB >> 28626853

Conjunctival melanoma in Southwestern Nigeria: a case series and review of literature.

Oluyemi Fasina1, Olayiwola A Oluwasola2.   

Abstract

PURPOSE: Conjunctival melanoma is a rare tumor worldwide and is extremely rare among black population. This study aims to report the demographics, clinical presentation, treatment, and outcome of patients seen in an indigenous black population in Southwestern Nigeria.
METHODS: All patients histologically diagnosed with conjunctival melanoma and managed in the facility were reviewed. Their demographics, clinical presentation, treatment received, outcome of treatment, and histopathological features were analyzed.
RESULTS: Six patients (males = 2) with a mean age of 49.8 years were managed over 11 years (range 25-75 years). The right eye was involved in three patients, while one patient had bilateral non-simultaneous tumor. All six patients presented with pigmented growth over the ocular surface of varying duration, confirmed as malignant melanoma at histopathology after an excision biopsy (two patients), incision biopsy (one patient), or orbital exenteration (three patients). One patient who had complete adjuvant treatment postoperatively remained alive and tumor-free at 7-year follow-up, one patient is presently on chemotherapy, one patient died while on admission, and the remaining three patients abandoned further postoperative treatment and defaulted from follow-up.
CONCLUSION: Conjunctival melanoma is a rare ocular malignancy in Southwestern Nigeria, and patients present with advanced disease with potential poor outcome.

Entities:  

Keywords:  Black population; Conjunctival malignant melanoma; Malignant melanoma; Nigeria; Outcome

Mesh:

Year:  2017        PMID: 28626853     DOI: 10.1007/s10792-017-0612-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  30 in total

1.  Malignant melanoma of conjunctiva following surgical excision of naevus.

Authors:  S M Betharia; S Vashisht; B R Kalra
Journal:  Indian J Ophthalmol       Date:  1985 Jul-Aug       Impact factor: 1.848

2.  Limbal melanoma in a Negro.

Authors:  R A Kielar
Journal:  Arch Ophthalmol       Date:  1972-04

3.  Epibulbar malignant melanoma in a black patient.

Authors:  N C Charles; S Stenson; H B Taterka
Journal:  Arch Ophthalmol       Date:  1979-02

4.  Conjunctival malignant melanoma in Sweden 1969-91.

Authors:  S Seregard; E Kock
Journal:  Acta Ophthalmol (Copenh)       Date:  1992-06

5.  Tumors of the eye and adnexa in Africans of Uganda.

Authors:  A C Templeton
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

6.  Malignant melanomas of the conjunctiva.

Authors:  V B Bernardino; M A Naidoff; W H Clark
Journal:  Am J Ophthalmol       Date:  1976-09       Impact factor: 5.258

7.  Ocular malignant melanoma in South African blacks.

Authors:  B Miller; C Abrahams; G C Cole; N S Proctor
Journal:  Br J Ophthalmol       Date:  1981-10       Impact factor: 4.638

Review 8.  Conjunctival melanoma in the black population.

Authors:  A D Singh; O E Campos; R M Rhatigan; J A Schulman; R P Misra
Journal:  Surv Ophthalmol       Date:  1998 Sep-Oct       Impact factor: 6.048

9.  C-myc oncogene expression in ocular melanomas.

Authors:  J A Royds; R M Sharrard; M A Parsons; J Lawry; R Rees; D Cottam; B Wagner; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

10.  Melanoma in black South Africans.

Authors:  D A Hudson; J E Krige
Journal:  J Am Coll Surg       Date:  1995-01       Impact factor: 6.113

View more
  1 in total

1.  Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study.

Authors:  Puneet Jain; Paul T Finger; Maria Fili; Bertil Damato; Sarah E Coupland; Heinrich Heimann; Nihal Kenawy; Niels J Brouwer; Marina Marinkovic; Sjoerd G Van Duinen; Jean Pierre Caujolle; Celia Maschi; Stefan Seregard; David Pelayes; Martin Folgar; Yacoub A Yousef; Hatem Krema; Brenda Gallie; Alberto Calle-Vasquez
Journal:  Br J Ophthalmol       Date:  2020-09-05       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.